Midcareer Investigator Award

描述(由申请人提供)：此次K24续签的长期目标是提高候选人的研究效率，并增加训练有素的临床研究人员，他们可以进行以患者为中心的研究，竞争同行评审的拨款，并指导下一代临床研究人员。具体目标是：(1)发展和扩大候选人以患者为中心的研究能力；(2)指导新的以患者为中心的研究人员。 候选人是一位在前列腺癌方面拥有特殊专业知识的内科肿瘤学家。他在以患者为导向的研究、独立的同行评审资金和有效的指导方面有着良好的记录。这位候选人的临床研究计划重点是前列腺癌的存活率和骨转移的预防和治疗。在K24的头5年里，这位候选人通过识别以前未知的雄激素剥夺疗法的危害和开发有效的前列腺癌新疗法，帮助改善了前列腺癌男性的临床护理。在这位K24的头五年里，候选人还成功地指导了10名以患者为导向的研究初级研究员。 这次K24的更新恰逢候选人研究计划的重要新方向。该研究计划围绕三个研究主题进行了开发和扩展：生存、生物标记物和新疗法。此次K24续签也与马萨诸塞州总医院、达纳·法伯哈佛癌症中心和哈佛催化剂确定了三名新的导师并计划扩大导师职责的时间不谋而合。这次K24更新的支持对于为候选人提供必要的保护时间来发展和扩大以患者为导向的研究和指导至关重要。

DESCRIPTION (provided by applicant): The broad long-term objectives of this K24 renewal are to enhance the research productivity of the candidate and to increase the pool of well-trained clinical researchers who can conduct patient-oriented research, compete for peer reviewed grants, and mentor the next generation of clinical investigators. The Specific Aims are to: (1) develop and expand the candidate's capabilities in patient-oriented research, and (2) mentor new investigators in patient-oriented research. The candidate is a medical oncologist with particular expertise in prostate cancer. He has a strong record of patient-oriented research, independent peer-reviewed funding, and effective mentoring. The candidate's clinical research program focuses on prostate cancer survivorship and the prevention and treatment of bone metastases. In the first 5 years of this K24, the candidate has helped improve the clinical care for men with prostate cancer by identifying previously unrecognized harms of androgen deprivation therapy and by developing effective new treatments for prostate cancer. In the first five years of this K24, the candidate has also successfully mentored 10 junior investigators in patient-oriented research. This K24 renewal coincides with important new directions in the candidate's research program. The research program has been developed and expanded around three research themes: survivorship, biomarkers, and novel therapy. This K24 renewal also coincides with the identification of three new mentees and planned expansion of mentoring responsibilities at Massachusetts General Hospital, Dana Farber Harvard Cancer Center, and the Harvard Catalyst. The support of this K24 renewal is essential to provide the candidate with the protected time necessary to develop and expand patient-oriented research and mentoring.